Latest News

April 28, 2023

JAMA Surgery publishes TAILORx analysis showing that racial and ethnic differences in locoregional breast cancer recurrence patterns are prevalent even in a clinical trial population with similar access to care

April 26, 2023

Two new studies shed light on cancer detection in dense breasts as researchers emphasize the need for the TMIST trial

April 26, 2023

An AI algorithm may help better guide oropharynx cancer treatment

April 21, 2023

Lancet Digital Health publishes the first validation of a CT-based deep learning tool for pre-treatment identification of head and neck cancer patients with high-risk, aggressive disease (in the context of the E3311 trial)

April 19, 2023

The March/April 2023 News from ECOG-ACRIN blog is now available

April 7, 2023

American College of Radiology (ACR) leader highlights TMIST mammography trial in testimony supporting NIH funding increase

April 6, 2023

E1411 study chair Mitchell Smith discusses the use of ibrutinib for patients with previously treated mantle cell lymphoma

March 23, 2023

The Spring 2023 advocacy blog Considering Clinical Trials is now available

March 21, 2023

In this video interview, Dr. Neha Vapiwala discusses the INDICATE (EA8191) trial and changing the trajectory of prostate cancer through radiation and imaging techniques


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
41

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group